Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Prelude Therapeutics Incorporated (PRLD)
USD4.50
+0.11 (+2.51%)
US NASDAQ Healthcare Biotechnology
Address
200 Powder Mill Road 19803
Wilmington, DE, US
Wilmington, DE, US
CEO
Krishna Vaddi
Website
preludetx.com
IPO
2020-09-25
CIK 1678660 ISIN US74065P1012
Description
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.50
+0.11 (+2.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
474.7K
Beta
1.01
Float Shares
40.28M
Free Float %
52.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.43% | -9.51% | +6.64% | +108.97% | +208.61% | +60.69% | +366.00% | -29.82% | -88.10% | -82.21% | -82.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (8 ratings, all time)
Buy
Price Targets & DCF
Current price
4.50
Low
8.00
+77.8%
Consensus
8.00
+77.8%
Median
8.00
+77.8%
High
8.00
+77.8%
DCF (Unlevered)
3.73
-17.2%
DCF (Levered)
1.02
-77.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
8.00
+77.8%
|
| Last Quarter | 1 |
8.00
+77.8%
|
| Last Year | 1 |
8.00
+77.8%
|
| All Time | 6 |
8.00
+77.8%
|
Quality scores
Altman Z-Score
-7.15
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+73.4% ★
-
EPS growth Biotechnology: +29.7%+23.2% Q1'26: +69.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-613.8% Q1'26: -473.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-861.3% Q1'26: -309.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +1,553.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.5% ★ Q1'26: +8.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.17× Q1'26: -0.32× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
7.00M
est: 1.50M (+366.7%)
|
12.14M
est: 17.50M (-30.6%)
|
26.15M
25.58M – 26.73M
+49.4% YoY
|
50.00M
50.00M – 50.00M
+91.2% YoY
|
200.00M
200.00M – 200.00M
+300.0% YoY
|
100.00M
100.00M – 100.00M
-50.0% YoY
|
551.52M
551.52M – 551.52M
+451.5% YoY
|
| EBITDA |
-137.94M
est: 300.0K (-46,080.8%)
|
-102.86M
est: 3.50M (-3,038.7%)
|
5.23M
5.11M – 5.34M
+49.4% YoY
|
10.00M
10.00M – 10.00M
+91.2% YoY
|
40.00M
40.00M – 40.00M
+300.0% YoY
|
20.00M
20.00M – 20.00M
-50.0% YoY
|
110.30M
110.30M – 110.30M
+451.5% YoY
|
| EBIT |
-139.71M
est: 300.0K (-46,671.5%)
|
-104.57M
est: 3.50M (-3,087.6%)
|
5.23M
5.11M – 5.34M
+49.4% YoY
|
10.00M
10.00M – 10.00M
+91.2% YoY
|
40.00M
40.00M – 40.00M
+300.0% YoY
|
20.00M
20.00M – 20.00M
-50.0% YoY
|
110.30M
110.30M – 110.30M
+451.5% YoY
|
| Net Income |
-127.17M
est: -137.22M (+7.3%)
|
-99.50M
est: -96.20M (-3.4%)
|
-46.56M
-46.56M – -46.56M
+51.6% YoY
|
-22.32M
-22.32M – -22.32M
+52.1% YoY
|
-2.69M
-5.76M – 375.8K
+87.9% YoY
|
-22.32M
-22.32M – -22.32M
-728.6% YoY
|
140.83M
140.83M – 140.83M
+731.0% YoY
|
| SGA |
28.72M
est: 2.68M (+969.8%)
|
22.41M
est: 31.32M (-28.5%)
|
46.80M
45.77M – 47.83M
+49.4% YoY
|
89.48M
89.48M – 89.48M
+91.2% YoY
|
357.93M
357.93M – 357.93M
+300.0% YoY
|
178.97M
178.97M – 178.97M
-50.0% YoY
|
987.04M
987.04M – 987.04M
+451.5% YoY
|
| EPS |
-1.68
est: -1.77 (+5.3%)
|
-1.29
est: -1.25 (-3.2%)
|
-0.61
-0.61 – -0.61
+51.6% YoY
|
-0.29
-0.29 – -0.29
+52.1% YoY
|
-0.04
-0.07 – 0.00
+87.9% YoY
|
-0.29
-0.29 – -0.29
-728.6% YoY
|
1.83
1.83 – 1.83
+731.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-61.85M
OE per share TTM
-0.72
Owner's Yield
-28.22%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
637.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
283.9K
Insider transactions (90d)
6
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | OrbiMed Advisors LLC | 14.81M | 33.90% | — | 14.81M | — | 10.00 | IA | Delaware | 2020-10-05 | ↗ |
| 2 | OrbiMed Capital GP VI LLC | 14.81M | 33.90% | — | 14.81M | — | 10.00 | OO | Delaware | 2020-10-05 | ↗ |
| 3 | Baker Bros. Advisors (GP) LLC | 10.12M | 31.10% | 10.12M | — | 10.12M | 10.00 | HC, OO | Delaware | 2020-09-30 | ↗ |
| 4 | Baker Bros. Advisors LP | 10.12M | 31.10% | 10.12M | — | 10.12M | 10.00 | IA, PN | Delaware | 2020-09-30 | ↗ |
| 5 | Felix J. Baker | 10.12M | 31.10% | 10.12M | — | 10.12M | 10.00 | HC, IN | United States | 2020-09-30 | ↗ |
| 6 | Julian C. Baker | 10.12M | 31.10% | 10.12M | — | 10.12M | 10.00 | HC, IN | United States | 2020-09-30 | ↗ |
| 7 | Abigail P. Johnson | 4.21M | 9.63% | — | — | 4.21M | — | IN | United States of America | 2021-02-08 | ↗ |
| 8 | FMR LLC | 4.21M | 9.63% | 420.4K | — | 4.21M | — | HC | Delaware | 2021-02-08 | ↗ |
| 9 | Krishna Vaddi | 3.62M | 9.70% | 3.62M | — | 3.62M | — | IN | — | 2022-02-04 | ↗ |
| 10 | Deerfield Management Company, L.P. | 3.22M | 7.68% | — | 3.22M | — | — | PN | Delaware | 2023-11-13 | ↗ |
| 11 | Deerfield Mgmt, L.P. | 3.22M | 7.68% | — | 3.22M | — | — | PN | Delaware | 2023-11-13 | ↗ |
| 12 | Deerfield Partners, L.P. | 3.22M | 7.68% | — | 3.22M | — | — | PN | Delaware | 2023-11-13 | ↗ |
| 13 | James E. Flynn | 3.22M | 7.68% | — | 3.22M | — | — | IN | United States | 2023-11-13 | ↗ |
| 14 | Management division of UBS Group AG (see Item 7) | 2.51M | 5.24% | — | — | — | — | HC | Switzerland | 2023-02-13 | ↗ |
| 15 | OrbiMed Capital LLC | 789.5K | 1.80% | 789.5K | — | 789.5K | 10.00 | IA | Cayman Islands | 2020-10-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
5
-44 vs prev Q
New positions
1
Closed positions
44
Increased
2
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10.91M +— (+0.0%) | 31.64M +15.9M (+101.4%) | 14.33% -0.026 pp | 0.65% +0.278 pp | USD28.09 -89.7% | 22 qtrs — |
| 2 | BAKER BROS. ADVISORS LP | 10.12M +— (+0.0%) | 29.36M +14.8M (+101.4%) | 13.30% -0.024 pp | 0.17% +0.067 pp | USD30.14 -90.4% | 22 qtrs — |
| 3 | VANGUARD GROUP INC | 1.41M +421.1K (+42.4%) | 4.10M +2.7M (+186.8%) | 1.86% +0.551 pp | 0.00% +0.000 pp | USD28.75 -89.9% | 22 qtrs — |
| 4 | KYNAM CAPITAL MANAGEMENT, LP | 788.9K +788.9K (+100.0%) | 2.29M +2.3M (+100.0%) | 1.04% +1.036 pp | 0.15% +0.146 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 788.7K +636.5K (+418.1%) | 2.29M +2.1M (+943.4%) | 1.04% +0.836 pp | 0.00% +0.003 pp | USD2.73 +6.2% | 19 qtrs — |
| 6 | PRICE T ROWE ASSOCIATES INC /MD/ | 756.0K -120.4K (-13.7%) | 2.19M +931.0K (+73.8%) | 0.99% -0.160 pp | 0.00% +0.000 pp | USD9.36 -69.0% | 22 qtrs — |
| 7 | ACADIAN ASSET MANAGEMENT LLC | 535.7K -4.9K (-0.9%) | 1.55M +774.0K (+99.6%) | 0.70% -0.008 pp | 0.00% +0.001 pp | USD1.41 +105.7% | 10 qtrs — |
| 8 | MORGAN STANLEY | 334.9K +50.7K (+17.8%) | 971.3K +562.0K (+137.3%) | 0.44% +0.066 pp | 0.00% +0.000 pp | USD8.73 -66.8% | 22 qtrs — |
| 9 | MARSHALL WACE, LLP | 273.9K +273.9K (+100.0%) | 794.3K +794.3K (+100.0%) | 0.36% +0.360 pp | 0.00% +0.001 pp | USD2.90 +0.0% | 6 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 272.9K +55.3K (+25.4%) | 791.5K +478.1K (+152.6%) | 0.36% +0.072 pp | 0.00% +0.000 pp | USD18.37 -84.2% | 21 qtrs — |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 271.3K -272.7K (-50.1%) | 786.8K +3.4K (+0.4%) | 0.36% -0.360 pp | 0.00% +0.000 pp | USD2.53 +14.6% | 17 qtrs — |
| 12 | BLACKROCK, INC. | 266.3K +1.3K (+0.5%) | 772.2K +390.7K (+102.4%) | 0.35% +0.001 pp | 0.00% +0.000 pp | USD2.07 +40.1% | 6 qtrs — |
| 13 | TWO SIGMA ADVISERS, LP | 237.3K +14.6K (+6.6%) | 688.2K +367.5K (+114.6%) | 0.31% +0.019 pp | 0.00% +0.001 pp | USD2.08 +39.4% | 17 qtrs — |
| 14 | TD ASSET MANAGEMENT INC | 160.7K +— (+0.0%) | 465.9K +234.6K (+101.4%) | 0.21% 0.000 pp | 0.00% +0.000 pp | USD8.82 -67.1% | 22 qtrs — |
| 15 | MILLENNIUM MANAGEMENT LLC | 151.0K -996.0K (-86.8%) | 437.9K -1.2M (-73.5%) | 0.20% -1.311 pp | 0.00% -0.001 pp | USD1.40 +107.1% | 22 qtrs — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 135.9K +135.9K (+100.0%) | 394.1K +394.1K (+100.0%) | 0.18% +0.179 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 5 qtrs — |
| 17 | STATE STREET CORP | 127.3K +29.7K (+30.4%) | 369.1K +228.6K (+162.7%) | 0.17% +0.039 pp | 0.00% +0.000 pp | USD8.12 -64.3% | 21 qtrs — |
| 18 | SPHERA FUNDS MANAGEMENT LTD. | 122.8K +122.8K (+100.0%) | 356.0K +356.0K (+100.0%) | 0.16% +0.161 pp | 0.07% +0.069 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 19 | GOLDMAN SACHS GROUP INC | 117.5K +38.2K (+48.1%) | 340.7K +226.5K (+198.2%) | 0.15% +0.050 pp | 0.00% +0.000 pp | USD2.89 +0.3% | 22 qtrs — |
| 20 | JANE STREET GROUP, LLC | 111.0K +76.2K (+218.9%) | 322.0K +271.9K (+542.2%) | 0.15% +0.100 pp | 0.00% +0.000 pp | USD2.24 +29.5% | 3 qtrs — |
| 21 | OMERS ADMINISTRATION CORP | 73.0K +73.0K (+100.0%) | 211.7K +211.7K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.002 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 22 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 70.5K +1.3K (+1.9%) | 200.4K +100.7K (+101.0%) | 0.09% +0.002 pp | 0.00% +0.000 pp | USD5.59 -48.1% | 16 qtrs — |
| 23 | POINT72 ASSET MANAGEMENT, L.P. | 59.2K +59.2K (+100.0%) | 171.6K +171.6K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 24 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 53.5K +— (+0.0%) | 155.2K +78.1K (+101.4%) | 0.07% 0.000 pp | 0.00% +0.002 pp | USD3.78 -23.3% | 15 qtrs — |
| 25 | XTX TOPCO LTD | 50.2K +34.6K (+222.0%) | 145.5K +123.0K (+548.5%) | 0.07% +0.045 pp | 0.00% +0.003 pp | USD2.48 +16.9% | 6 qtrs — |
| 26 | NORTHERN TRUST CORP | 50.1K +13.7K (+37.6%) | 145.3K +92.9K (+177.1%) | 0.07% +0.018 pp | 0.00% +0.000 pp | USD8.77 -66.9% | 21 qtrs — |
| 27 | COLONY GROUP, LLC | 50.0K +50.0K (+100.0%) | 145.0K +145.0K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 28 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 46.1K +46.1K (+100.0%) | 133.7K +133.7K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 29 | CERITY PARTNERS LLC | 33.0K -1.4K (-4.0%) | 95.6K +46.1K (+93.3%) | 0.04% -0.002 pp | 0.00% +0.000 pp | USD1.95 +48.7% | 8 qtrs — |
| 30 | QUBE RESEARCH & TECHNOLOGIES LTD | 21.6K +21.6K (+100.0%) | 62.5K +62.5K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 31 | PRUDENTIAL FINANCIAL INC | 15.5K -10.3K (-39.9%) | 45.0K +7.8K (+21.0%) | 0.02% -0.014 pp | 0.00% +0.000 pp | USD1.44 +101.4% | 2 qtrs — |
| 32 | HSBC HOLDINGS PLC | 13.7K -95.0 (-0.7%) | 39.5K +19.2K (+95.2%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD3.20 -9.4% | 10 qtrs — |
| 33 | BANK OF AMERICA CORP /DE/ | 9.8K +960.0 (+10.8%) | 28.4K +15.7K (+123.2%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD4.49 -35.4% | 21 qtrs — |
| 34 | BARCLAYS PLC | 8.6K -18.6K (-68.3%) | 24.9K -31.3K (-55.6%) | 0.01% -0.024 pp | 0.00% +0.000 pp | USD1.97 +47.2% | 16 qtrs — |
| 35 | FMR LLC | 6.2K -2.9K (-32.4%) | 17.8K +4.7K (+36.2%) | 0.01% -0.004 pp | 0.00% +0.000 pp | USD11.81 -75.4% | 22 qtrs — |
| 36 | SBI SECURITIES CO., LTD. | 2.7K +— (+0.0%) | 7.9K +4.0K (+101.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.27 +128.3% | 5 qtrs — |
| 37 | CALDWELL SUTTER CAPITAL, INC. | 2.0K +2.0K (+100.0%) | 5.8K +5.8K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.003 pp | USD2.90 +0.0% | 1 qtrs NEW |
| 38 | UBS GROUP AG | 1.9K -2.3K (-55.5%) | 5.4K -621.0 (-10.3%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD1.31 +121.4% | 22 qtrs — |
| 39 | ROYAL BANK OF CANADA | 1.7K -6.0K (-77.4%) | 5.0K -6.0K (-54.5%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD4.99 -41.9% | 21 qtrs — |
| 40 | NISA INVESTMENT ADVISORS, LLC | 1.6K +— (+0.0%) | 4.7K +2.4K (+101.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.92 +215.2% | 7 qtrs — |
| 41 | PNC FINANCIAL SERVICES GROUP, INC. | 1.2K +— (+0.0%) | 3.4K +1.7K (+101.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.93 +211.8% | 7 qtrs — |
| 42 | CWM, LLC | 692.00 -527.0 (-43.2%) | 2.0K +— (+0.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.01 +187.1% | 5 qtrs — |
| 43 | GROUP ONE TRADING, L.P. | 500.00 +— (+0.0%) | 1.5K +730.0 (+101.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.07 +40.1% | 6 qtrs — |
| 44 | BNP PARIBAS ARBITRAGE, SNC | 95.00 +43.0 (+82.7%) | 276.00 +201.0 (+268.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 +45.0% | 5 qtrs — |
| 45 | JPMORGAN CHASE & CO | 62.00 -3.8K (-98.4%) | 180.00 -5.4K (-96.8%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD1.61 +80.1% | 21 qtrs — |
| 46 | OPTIVER HOLDING B.V. | 20.00 +— (+0.0%) | 58.00 +29.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.40 +107.1% | 2 qtrs — |
| 47 | CITIGROUP INC | 1.00 -6.0K (-100.0%) | 3.00 -8.6K (-100.0%) | 0.00% -0.008 pp | 0.00% +0.000 pp | USD2.00 +45.0% | 21 qtrs — |
| 48 | IFP ADVISORS, INC | 1.00 -17.0 (-94.4%) | 3.00 -23.0 (-88.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs — |
| 49 | TOWER RESEARCH CAPITAL LLC (TRC) | — -6.9K (-100.0%) | — -10.0K (-100.0%) | 0.00% -0.009 pp | 0.00% 0.000 pp | USD— | 21 qtrs SOLD |
| 50 | GSA CAPITAL PARTNERS LLP | — -75.2K (-100.0%) | — -108.0K (-100.0%) | 0.00% -0.099 pp | 0.00% -0.009 pp | USD— | 3 qtrs SOLD |
| 51 | HRT FINANCIAL LP | — -16.9K (-100.0%) | — -24.0K (-100.0%) | 0.00% -0.022 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 52 | SRS CAPITAL ADVISORS, INC. | — -15.0 (-100.0%) | — -22.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 53 | AQR CAPITAL MANAGEMENT LLC | — -10.5K (-100.0%) | — -15.1K (-100.0%) | 0.00% -0.014 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 54 | SHAY CAPITAL LLC | — -100.0K (-100.0%) | — -144.0K (-100.0%) | 0.00% -0.132 pp | 0.00% -0.013 pp | USD— | 3 qtrs SOLD |
| 55 | EVERSOURCE WEALTH ADVISORS, LLC | — -89.0 (-100.0%) | — -128.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 38 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.03% | 94.4K | 0.39% |
| 2 | iShares Micro-Cap ETF IWC | 0.03% | 447.2K | 0.60% |
| 3 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.26M | 0.24% |
| 4 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.00% | 124.2K | 0.30% |
| 5 | Global X - Russell 2000 ETF RSSL | 0.00% | 62.4K | 0.08% |
| 6 | Invesco Russell 2000 UCITS ETF RTYS.L | 0.00% | 13.5K | 0.25% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.00% | 2.2K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.00% | 3.22M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.00% | 21.0K | 0.36% |
| 10 | ProShares - Ultra Russell2000 UWM | 0.00% | 5.3K | 1.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
7.00
Bullish
Ratio by volume
3.00
Bullish
Buys
7
Sells
1
Shares acquired
9.29M
Shares disposed
1.41M
Cash buys
6.00
Cash sales
—
Net activity
+7,882,882
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Morris Charles Q | Officer | A-Award | A | Employee Stock Option (right to buy) | 450,000 | 4.70 | 2.12M | 450,000 | D | ↗ |
| 2026-04-27 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J-Other | D | Common Stock | 1,407,000 | 0.00 | 140.70 | 6,475,882 | I | ↗ |
| 2026-04-21 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 7,882,882 | I | ↗ |
| 2026-04-21 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 1,689,189 | 4.44 | 7.50M | 11,808,945 | I | ↗ |
| 2026-04-21 | Bonita David P | Director / 10% Owner | P-Purchase | A | Common Stock | 1,126,126 | 4.44 | 5.00M | 1,126,126 | I | ↗ |
| 2026-04-21 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Warrants to purchase Common Stock | 2,137,651 | 0.00 | 213.77 | 20,105,994 | I | ↗ |
| 2026-04-15 | Morris Charles Q | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-05 | Brusky Sean P. | Officer | — | — | Common Stock | 0 | 0.00 | — | 100,000 | D | ↗ |
| 2026-02-04 | Vaddi Krishna | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 837,000 | 2.30 | 1.93M | 837,000 | D | ↗ |
| 2026-02-04 | Scherle Peggy | Officer | A-Award | A | Employee Stock Option (right to buy) | 230,000 | 2.30 | 529.0K | 230,000 | D | ↗ |
| 2026-02-04 | Lim Bryant David | Officer | A-Award | A | Employee Stock Option (right to buy) | 275,000 | 2.30 | 632.5K | 275,000 | D | ↗ |
| 2026-02-04 | Combs Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 230,000 | 2.30 | 529.0K | 230,000 | D | ↗ |
| 2025-11-05 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 121,285 | 1.39 | 168.6K | 121,285 | D | ↗ |
| 2025-10-17 | Dorton Katina | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-04 | Huang Jane | Officer | F-InKind | D | Common Stock | 3,355 | 1.47 | 4.9K | 86,917 | D | ↗ |
| 2025-07-04 | Huang Jane | Officer | M-Exempt | A | Common Stock | 9,375 | 0.00 | — | 84,252 | D | ↗ |
| 2025-06-12 | Scherer Paul C | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-12 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 38,000 | 1.04 | 39.5K | 38,000 | D | ↗ |
| 2025-06-12 | FRIEDMAN PAUL A | Director | A-Award | A | Director Stock Option (Right to Buy) | 38,000 | 1.04 | 39.5K | 38,000 | D | ↗ |
| 2025-06-12 | Dier Mardi | Director | A-Award | A | Director Stock Option (Right to Buy) | 38,000 | 1.04 | 39.5K | 38,000 | D | ↗ |
| 2025-06-12 | Bonita David P | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 38,000 | 1.04 | 39.5K | 38,000 | D | ↗ |
| 2025-06-12 | Babler Martin | Director | A-Award | A | Director Stock Option (Right to Buy) | 38,000 | 1.04 | 39.5K | 38,000 | D | ↗ |
| 2025-06-12 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non- Qualified Stock Option (right to buy) | 76,000 | 1.04 | 79.0K | 76,000 | I | ↗ |
| 2025-04-04 | Huang Jane | Officer | F-InKind | D | Common Stock | 3,355 | 0.68 | 2.3K | 74,877 | D | ↗ |
| 2025-03-25 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 675,000 | 0.69 | 467.4K | 1,999,296 | D | ↗ |
| 2025-03-25 | Combs Andrew | Officer | P-Purchase | A | Common Stock | 100,000 | 0.69 | 69.3K | 480,123 | D | ↗ |
| 2025-03-21 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.73 | 11.0K | 1,324,296 | D | ↗ |
| 2025-03-20 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 5,416 | 0.73 | 4.0K | 1,309,296 | D | ↗ |
| 2025-03-17 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 9,106 | 0.75 | 6.8K | 1,303,880 | D | ↗ |
| 2025-03-14 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 29,999 | 0.75 | 22.6K | 1,294,774 | D | ↗ |
| 2025-03-13 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 0.72 | 35.8K | 1,264,775 | D | ↗ |
| 2025-03-12 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 47,500 | 0.71 | 33.7K | 1,214,775 | D | ↗ |
| 2025-02-04 | Vaddi Krishna | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 496,000 | 1.11 | 550.6K | 496,000 | D | ↗ |
| 2025-02-04 | Scherle Peggy | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 1.11 | 194.3K | 175,000 | D | ↗ |
| 2025-02-04 | Lim Bryant David | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.11 | 222.0K | 200,000 | D | ↗ |
| 2025-02-04 | Huang Jane | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 1.11 | 222.0K | 200,000 | D | ↗ |
| 2025-02-04 | Combs Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 1.11 | 194.3K | 175,000 | D | ↗ |
| 2025-01-04 | Huang Jane | Officer | M-Exempt | A | Common Stock | 9,375 | 0.00 | — | 72,716 | D | ↗ |
| 2024-12-31 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 1.21 | 6.0K | 142,553 | I | ↗ |
| 2024-12-30 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 1.20 | 12.0K | 137,553 | I | ↗ |
| 2024-12-23 | Combs Andrew | Officer | P-Purchase | A | Common Stock | 60,000 | 1.37 | 82.0K | 377,623 | D | ↗ |
| 2024-12-20 | Combs Andrew | Officer | P-Purchase | A | Common Stock | 3,075 | 1.15 | 3.5K | 317,623 | D | ↗ |
| 2024-12-19 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 6,888 | 0.89 | 6.1K | 127,553 | I | ↗ |
| 2024-12-19 | Lim Bryant David | Officer | P-Purchase | A | Common Stock | 25,000 | 0.91 | 22.6K | 27,400 | D | ↗ |
| 2024-12-18 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.93 | 93.2K | 1,167,275 | D | ↗ |
| 2024-07-04 | Huang Jane | Officer | M-Exempt | D | Restricted Stock Unit | 9,375 | 0.00 | — | 65,625 | — | ↗ |
| 2024-06-14 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 3.90 | 91.7K | 23,500 | — | ↗ |
| 2024-06-14 | FRIEDMAN PAUL A | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 3.90 | 91.7K | 23,500 | — | ↗ |
| 2024-06-14 | Dier Mardi | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 3.90 | 91.7K | 23,500 | — | ↗ |
| 2024-06-14 | Bonita David P | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 3.90 | 91.7K | 23,500 | — | ↗ |
| 2024-06-14 | Babler Martin | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 3.90 | 91.7K | 23,500 | — | ↗ |
| 2024-06-14 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non- Qualified Stock Option (right to buy) | 23,500 | 3.90 | 91.7K | 23,500 | — | ↗ |
| 2024-05-14 | Lim Bryant David | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 3.86 | 96.5K | 25,000 | — | ↗ |
| 2024-04-04 | Huang Jane | Officer | M-Exempt | A | Common Stock | 9,375 | 0.00 | — | 54,634 | — | ↗ |
| 2024-03-01 | Vaddi Krishna | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 425,000 | 4.59 | 1.95M | 425,000 | — | ↗ |
| 2024-03-01 | Scherle Peggy | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 4.59 | 688.5K | 150,000 | — | ↗ |
| 2024-03-01 | Lim Bryant David | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 4.59 | 688.5K | 150,000 | — | ↗ |
| 2024-03-01 | Huang Jane | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 4.59 | 803.3K | 175,000 | — | ↗ |
| 2024-03-01 | Combs Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 4.59 | 688.5K | 150,000 | — | ↗ |
| 2024-03-01 | Chardonnet Laurent | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 4.59 | 688.5K | 150,000 | — | ↗ |
| 2024-01-04 | Huang Jane | Officer | M-Exempt | D | Restricted Stock Unit | 9,375 | 0.00 | — | 84,375 | — | ↗ |
| 2023-12-13 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Warrants to purchase Common Stock | 7,343,307 | 0.00 | 734.33 | 17,968,343 | — | ↗ |
| 2023-10-04 | Huang Jane | Officer | M-Exempt | A | Common Stock | 9,375 | 0.00 | — | 39,728 | — | ↗ |
| 2023-07-04 | Huang Jane | Officer | M-Exempt | D | Restricted Stock Unit | 9,375 | 0.00 | — | 103,125 | — | ↗ |
| 2023-06-16 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 5.56 | 130.7K | 23,500 | — | ↗ |
| 2023-06-16 | FRIEDMAN PAUL A | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 5.56 | 130.7K | 23,500 | — | ↗ |
| 2023-06-16 | Dier Mardi | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 5.56 | 130.7K | 23,500 | — | ↗ |
| 2023-06-16 | Bonita David P | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 5.56 | 130.7K | 23,500 | — | ↗ |
| 2023-06-16 | Babler Martin | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,500 | 5.56 | 130.7K | 23,500 | — | ↗ |
| 2023-06-16 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non- Qualified Stock Option (right to buy) | 23,500 | 5.56 | 130.7K | 23,500 | — | ↗ |
| 2023-05-25 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 900 | 5.31 | 4.8K | 1,067,275 | — | ↗ |
| 2023-05-24 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 5.01 | 5.0K | 1,066,375 | — | ↗ |
| 2023-05-24 | Lim Bryant David | Officer | P-Purchase | A | Common Stock | 2,400 | 5.39 | 12.9K | 2,400 | — | ↗ |
| 2023-05-23 | Vaddi Krishna | Director / Officer | P-Purchase | A | Common Stock | 11,856 | 5.63 | 66.7K | 1,065,375 | — | ↗ |
| 2023-05-23 | Chardonnet Laurent | Officer | P-Purchase | A | Common Stock | 5,000 | 5.50 | 27.5K | 42,165 | — | ↗ |
| 2023-05-22 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 869,565 | 5.75 | 5.00M | 10,119,756 | — | ↗ |
| 2023-05-22 | Bonita David P | Director / 10% Owner | P-Purchase | A | Common Stock | 869,565 | 5.75 | 5.00M | 10,119,756 | — | ↗ |
| 2023-05-22 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Warrants to purchase Common Stock | 10,625,036 | 0.00 | 1.1K | 10,625,036 | — | ↗ |
| 2023-04-06 | Huang Jane | Officer | S-Sale | D | Common Stock | 13,280 | 6.12 | 81.3K | 24,220 | — | ↗ |
| 2023-04-04 | Huang Jane | Officer | M-Exempt | D | Restricted Stock Unit | 37,500 | 0.00 | — | 112,500 | — | ↗ |
| 2023-03-01 | Lim Bryant David | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,000 | 5.93 | 1.48M | 250,000 | — | ↗ |
| 2023-02-20 | Lim Bryant David | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-07 | Vaddi Krishna | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 330,000 | 7.20 | 2.38M | 330,000 | — | ↗ |
| 2023-02-07 | Scherle Peggy | Officer | A-Award | A | Employee Stock Option (right to buy) | 135,000 | 7.20 | 972.0K | 135,000 | — | ↗ |
| 2023-02-07 | Huang Jane | Officer | A-Award | A | Employee Stock Option (right to buy) | 150,000 | 7.20 | 1.08M | 150,000 | — | ↗ |
| 2023-02-07 | Combs Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 135,000 | 7.20 | 972.0K | 135,000 | — | ↗ |
| 2023-02-07 | Chardonnet Laurent | Officer | A-Award | A | Employee Stock Option (right to buy) | 135,000 | 7.20 | 972.0K | 135,000 | — | ↗ |
| 2022-12-21 | Chardonnet Laurent | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2022-12-20 | Vaddi Krishna | Director | P-Purchase | A | Common Stock | 19,188 | 5.13 | 98.4K | 120,665 | — | ↗ |
| 2022-12-08 | Chardonnet Laurent | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.76 | 47.6K | 35,873 | — | ↗ |
| 2022-06-17 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 34,300 | 0.00 | — | 34,300 | — | ↗ |
| 2022-06-17 | FRIEDMAN PAUL A | Director | A-Award | A | Director Stock Option (Right to Buy) | 34,300 | 0.00 | — | 34,300 | — | ↗ |
| 2022-06-17 | Dier Mardi | Director | A-Award | A | Director Stock Option (Right to Buy) | 34,300 | 0.00 | — | 34,300 | — | ↗ |
| 2022-06-17 | Bonita David P | Director | A-Award | A | Director Stock Option (Right to Buy) | 34,300 | 0.00 | — | 34,300 | — | ↗ |
| 2022-06-17 | Baker Brothers Life Sciences LP | Director | A-Award | A | Non-Qualified Stock Options (right to buy) | 34,300 | 0.00 | — | 34,300 | — | ↗ |
| 2022-06-17 | Babler Martin | Director | A-Award | A | Director Stock Option (Right to Buy) | 31,293 | 4.74 | 148.3K | 31,293 | — | ↗ |
| 2022-06-17 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 34,300 | 4.74 | 162.6K | 34,300 | — | ↗ |
| 2022-06-01 | Chardonnet Laurent | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.23 | 42.3K | 24,500 | — | ↗ |
| 2022-05-02 | Huang Jane | Officer | A-Award | A | Restricted Stock Unit | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-04-04 | Huang Jane | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-01 | Combs Andrew | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 36,062 | 1.89 | 68.2K | 50,397 | — | ↗ |
| 2022-03-31 | Combs Andrew | Officer | M-Exempt | A | Common Stock | 36,062 | 1.89 | 68.2K | 304,442 | — | ↗ |
| 2022-03-21 | Chardonnet Laurent | Officer | A-Award | A | Common Stock | 6,500 | 7.51 | 48.8K | 14,500 | — | ↗ |
| 2022-02-15 | Vaddi Krishna | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 327,900 | 10.58 | 3.47M | 327,900 | — | ↗ |
| 2022-02-15 | Scherle Peggy | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 10.58 | 1.06M | 100,000 | — | ↗ |
| 2022-02-15 | Morosini Deborah | Officer | A-Award | A | Employee Stock Option (right to buy) | 90,000 | 10.58 | 952.2K | 90,000 | — | ↗ |
| 2022-02-15 | Combs Andrew | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 10.58 | 1.06M | 100,000 | — | ↗ |
| 2022-02-15 | Chardonnet Laurent | Officer | A-Award | A | Employee Stock Option (right to buy) | 90,000 | 10.58 | 952.2K | 90,000 | — | ↗ |
| 2022-01-03 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 11,206 | 13.22 | 148.1K | 11,206 | — | ↗ |
| 2021-12-15 | Morosini Deborah | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 882 | 12.85 | 11.3K | 195,163 | — | ↗ |
| 2021-12-14 | Combs Andrew | Officer | P-Purchase | A | Common Stock | 4,000 | 11.60 | 46.4K | 268,380 | — | ↗ |
| 2021-12-13 | Vaddi Krishna | Director / Officer | A-Award | A | Common Stock | 8,000 | 12.13 | 97.0K | 1,053,519 | — | ↗ |
| 2021-12-13 | Combs Andrew | Officer | P-Purchase | A | Common Stock | 4,000 | 12.12 | 48.5K | 264,380 | — | ↗ |
| 2021-12-13 | Chardonnet Laurent | Officer | A-Award | A | Common Stock | 5,000 | 12.28 | 61.4K | 8,000 | — | ↗ |
| 2021-11-29 | Chardonnet Laurent | Officer | — | D | Common Stock | 0 | 0.00 | — | 3,000 | — | ↗ |
| 2021-11-16 | Morosini Deborah | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 28,751 | 12.85 | 369.5K | 196,045 | — | ↗ |
| 2021-10-13 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 8,022 | 15.81 | 126.8K | 8,022 | — | ↗ |
| 2021-10-05 | Mauro David J | Officer | M-Exempt | A | Common Stock | 15,000 | 1.89 | 28.4K | 15,000 | — | ↗ |
| 2021-09-07 | Mauro David J | Officer | S-Sale | D | Common Stock | 4,640 | 37.79 | 175.3K | 0 | — | ↗ |
| 2021-09-02 | Pierce Christopher | Officer | S-Sale | D | Common Stock | 6,727 | 41.52 | 279.3K | 10,680 | — | ↗ |
| 2021-08-27 | Scherle Peggy | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 6,014 | 1.43 | 8.6K | 27,018 | — | ↗ |
| 2021-08-26 | Scherle Peggy | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 1,700 | 1.43 | 2.4K | 33,032 | — | ↗ |
| 2021-08-25 | Piper Brian | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 8,333 | 1.89 | 15.7K | 264,329 | — | ↗ |
| 2021-08-13 | Scherle Peggy | Officer | S-Sale | D | Common Stock | 2,286 | 35.07 | 80.2K | 172,920 | — | ↗ |
| 2021-08-05 | Mauro David J | Officer | S-Sale | D | Common Stock | 6,721 | 32.15 | 216.1K | 100 | — | ↗ |
| 2021-07-27 | Scherle Peggy | Officer | M-Exempt | A | Common Stock | 20,000 | 1.43 | 28.6K | 192,920 | — | ↗ |
| 2021-07-20 | Vaddi Krishna | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 285,800 | 31.23 | 8.93M | 285,800 | — | ↗ |
| 2021-07-20 | Scherle Peggy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 95,000 | 31.23 | 2.97M | 95,000 | — | ↗ |
| 2021-07-20 | Piper Brian | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 115,650 | 31.23 | 3.61M | 115,650 | — | ↗ |
| 2021-07-20 | Pierce Christopher | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 85,000 | 31.23 | 2.65M | 85,000 | — | ↗ |
| 2021-07-20 | Morosini Deborah | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 85,000 | 31.23 | 2.65M | 85,000 | — | ↗ |
| 2021-07-20 | Mauro David J | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 95,000 | 31.23 | 2.97M | 95,000 | — | ↗ |
| 2021-07-20 | Combs Andrew | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 95,000 | 31.23 | 2.97M | 95,000 | — | ↗ |
| 2021-07-19 | Babler Martin | Director | A-Award | A | Employee Stock Option (Right to Buy) | 36,400 | 31.37 | 1.14M | 36,400 | — | ↗ |
| 2021-07-06 | Mauro David J | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 15,000 | 1.89 | 28.4K | 182,610 | — | ↗ |
| 2021-06-18 | Sandor Victor | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,344 | 31.02 | 724.1K | 23,344 | — | ↗ |
| 2021-06-18 | FRIEDMAN PAUL A | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,344 | 31.02 | 724.1K | 23,344 | — | ↗ |
| 2021-06-18 | Dier Mardi | Director | A-Award | A | Director Stock Option (Right to Buy) | 23,344 | 31.02 | 724.1K | 23,344 | — | ↗ |
| 2021-06-18 | Bonita David P | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 23,344 | 31.02 | 724.1K | 23,344 | — | ↗ |
| 2021-06-18 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Non-Qualified Stock Options (right to buy) | 23,344 | 31.02 | 724.1K | 23,344 | — | ↗ |
| 2021-06-07 | Mauro David J | Officer | M-Exempt | D | Common Stock | 15,000 | 1.89 | 28.4K | 197,610 | — | ↗ |
| 2021-05-25 | Piper Brian | Officer | M-Exempt | A | Common Stock | 8,333 | 1.89 | 15.7K | 8,333 | — | ↗ |
| 2021-05-07 | Scherle Peggy | Officer | S-Sale | D | Common Stock | 3,964 | 40.30 | 159.7K | 178,956 | — | ↗ |
| 2021-05-05 | Mauro David J | Officer | S-Sale | D | Common Stock | 10,476 | 40.30 | 422.1K | 1,109 | — | ↗ |
| 2021-04-29 | Pierce Christopher | Officer | M-Exempt | A | Common Stock | 3,295 | 1.89 | 6.2K | 7,045 | — | ↗ |
| 2021-04-29 | Morosini Deborah | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 3,223 | 1.89 | 6.1K | 4,323 | — | ↗ |
| 2021-04-27 | Mauro David J | Officer | S-Sale | D | Common Stock | 1,711 | 36.11 | 61.8K | 0 | — | ↗ |
| 2021-04-19 | Mauro David J | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 25,000 | 1.89 | 47.3K | 252,610 | — | ↗ |
| 2021-04-08 | Scherle Peggy | Officer | S-Sale | D | Common Stock | 1,417 | 36.97 | 52.4K | 176,133 | — | ↗ |
| 2021-04-08 | Pierce Christopher | Officer | S-Sale | D | Common Stock | 200 | 40.00 | 8.0K | 3,750 | — | ↗ |
| 2021-04-08 | Morosini Deborah | Officer | M-Exempt | A | Common Stock | 100 | 1.89 | 189.00 | 544 | — | ↗ |
| 2021-04-08 | Mauro David J | Officer | M-Exempt | A | Common Stock | 9,617 | 1.89 | 18.2K | 9,617 | — | ↗ |
| 2021-04-07 | Scherle Peggy | Officer | S-Sale | D | Common Stock | 8,289 | 39.02 | 323.4K | 180,001 | — | ↗ |
| 2021-04-07 | Pierce Christopher | Officer | S-Sale | D | Common Stock | 828 | 40.08 | 33.2K | 3,750 | — | ↗ |
| 2021-04-07 | Morosini Deborah | Officer | S-Sale | D | Common Stock | 1,000 | 40.04 | 40.0K | 444 | — | ↗ |
| 2021-04-07 | Mauro David J | Officer | M-Exempt | A | Common Stock | 15,383 | 1.89 | 29.1K | 15,383 | — | ↗ |
| 2021-01-27 | BAKER BROS. ADVISORS LP | Director / 10% Owner | M-Exempt | A | Common Stock | 5,188 | 12.85 | 66.7K | 876,061 | — | ↗ |
| 2021-01-11 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Non-Voting Common Stock | 41,700 | 0.00 | — | 5,596,886 | — | ↗ |
| 2021-01-11 | Bonita David P | Director / 10% Owner | P-Purchase | A | Non-Voting Common Stock | 41,700 | 0.00 | — | 5,596,886 | — | ↗ |
| 2021-01-11 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Non-Voting Common Stock | 12,444 | 0.00 | — | 509,480 | — | ↗ |
| 2020-09-29 | Vaddi Krishna | Director / Officer | C-Conversion | D | Series A Preferred Stock | 32,876 | 0.00 | — | 0 | — | ↗ |
| 2020-09-29 | Pierce Christopher | Officer | P-Purchase | A | Common Stock | 3,750 | 19.00 | 71.3K | 3,750 | — | ↗ |
| 2020-09-29 | ORBIMED ADVISORS LLC | Director / 10% Owner | C-Conversion | D | Series A Prefered Stock | 2,196,494 | 0.00 | — | 0 | — | ↗ |
| 2020-09-29 | Morosini Deborah | Officer | P-Purchase | A | Common Stock | 444 | 19.00 | 8.4K | 444 | — | ↗ |
| 2020-09-29 | FRIEDMAN PAUL A | Director | C-Conversion | A | Common Stock | 152,576 | 0.00 | — | 500,098 | — | ↗ |
| 2020-09-29 | Dier Mardi | Director | P-Purchase | A | Common Stock | 10,000 | 19.00 | 190.0K | 10,000 | — | ↗ |
| 2020-09-29 | Combs Andrew | Officer | P-Purchase | A | Common Stock | 1,000 | 19.00 | 19.0K | 260,380 | — | ↗ |
| 2020-09-29 | Bonita David P | Director / 10% Owner | C-Conversion | D | Series C Preferred Stock | 413,234 | 0.00 | — | 0 | — | ↗ |
| 2020-09-29 | BAKER BROS. ADVISORS LP | Director / 10% Owner | C-Conversion | A | Common Stock | 370,552 | 0.00 | — | 720,721 | — | ↗ |
| 2020-09-25 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 526,300 | 19.00 | 10.00M | 526,300 | — | ↗ |
| 2020-09-25 | Bonita David P | Director / 10% Owner | P-Purchase | A | Common Stock | 710,500 | 19.00 | 13.50M | 917,412 | — | ↗ |
| 2020-09-24 | Vaddi Krishna | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 518,898 | — | ↗ |
| 2020-09-24 | Scherle Peggy | Officer | — | D | Employee Stock Option (right to buy) | 43,230 | 1.43 | 61.8K | 0 | — | ↗ |
| 2020-09-24 | Sandor Victor | Director | — | D | Director Stock Option (right to buy) | 43,230 | 1.89 | 81.7K | 0 | — | ↗ |
| 2020-09-24 | Piper Brian | Officer | — | D | Employee Stock Option (right to buy) | 116,720 | 12.85 | 1.50M | 0 | — | ↗ |
| 2020-09-24 | Pierce Christopher | Officer | — | D | Employee Stock Option (right to buy) | 224,796 | 12.85 | 2.89M | 0 | — | ↗ |
| 2020-09-24 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | I | Series B Preferred Stock | 2,945,458 | 0.00 | — | 0 | — | ↗ |
| 2020-09-24 | Neu Kelvin | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-24 | Morosini Deborah | Officer | — | D | Employee Stock Option (right to buy) | 8,646 | 1.89 | 16.3K | 0 | — | ↗ |
| 2020-09-24 | Mauro David J | Officer | — | D | Employee Stock Option (right to buy) | 142,658 | 12.85 | 1.83M | 0 | — | ↗ |
| 2020-09-24 | FRIEDMAN PAUL A | Director | — | D | Common Stock | 0 | 0.00 | — | 51,728 | — | ↗ |
| 2020-09-24 | Dier Mardi | Director | A-Award | A | Director Stock Option (right to buy) | 3,458 | 19.00 | 65.7K | 3,458 | — | ↗ |
| 2020-09-24 | Combs Andrew | Officer | — | D | Common Stock | 0 | 0.00 | — | 259,380 | — | ↗ |
| 2020-09-24 | Bonita David P | Director / 10% Owner | — | I | Series A Preferred Stock | 2,196,494 | 0.00 | — | 0 | — | ↗ |
| 2020-09-24 | BAKER BROS. ADVISORS LP | Director / 10% Owner | — | I | Series A Convertible Preferred Stock | 1,976,841 | 0.00 | — | 0 | — | ↗ |
| 2020-08-21 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Series C Preferred Stock | 1,033,084 | 0.00 | — | 1,033,084 | — | ↗ |
| 2020-08-21 | Bonita David P | Director / 10% Owner | P-Purchase | A | Series C Preferred Stock | 1,033,084 | 0.00 | — | 1,033,084 | — | ↗ |
| 2020-08-21 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Series C Preferred Stock | 75,873 | 0.00 | — | 75,873 | — | ↗ |
| 2020-03-27 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Series B Preferred Stock | 3,681,822 | 0.00 | — | 7,363,644 | — | ↗ |
| 2020-03-27 | FRIEDMAN PAUL A | Director | P-Purchase | A | Series B Preferred Stock | 76,288 | 0.00 | — | 152,576 | — | ↗ |
| 2020-03-27 | Bonita David P | Director / 10% Owner | P-Purchase | A | Series B Preferred Stock | 3,681,822 | 0.00 | — | 7,363,644 | — | ↗ |
| 2020-03-27 | BAKER BROS. ADVISORS LP | Director / 10% Owner | P-Purchase | A | Series B Preferred Stock | 308,793 | 0.00 | — | 308,793 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-8.0K
Shares Outstanding
76.84M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Krishna Vaddi, Ph.D. Chief Executive Officer | 615.4K | — | — | 412.7K | 309.5K | 10.4K | 1.35M | 30.62% | ↗ |
| 2 | 2025 | Bryant D. Lim Chief Legal Officer, Corporate Secretary, and Chief Financial Officer | 477.5K | — | — | 166.3K | 193.2K | 10.4K | 847.4K | 19.63% | ↗ |
| 3 | 2025 | Peggy A. Scherle, Ph. D. Chief Scientific Officer | 473.4K | — | — | 145.5K | 190.4K | 10.4K | 819.7K | 17.75% | ↗ |
| 4 | 2024 | Krishna Vaddi, Ph.D. Chief Executive Officer | 594.2K | — | — | 1.45M | 276.6K | 10.4K | 2.33M | 62.14% | ↗ |
| 5 | 2024 | Jane Huang, M.D. President and Chief Medical Officer | 568.3K | — | — | 595.7K | 264.6K | 10.4K | 1.44M | 41.40% | ↗ |
| 6 | 2024 | Bryant D. Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | 444.2K | — | — | 581.9K | 166.5K | 10.4K | 1.20M | 48.37% | ↗ |
| 7 | 2024 | Bryant D. Lim Chief Legal Officer, Corporate Secretary, and Chief Financial Officer | 444.2K | — | — | 581.9K | 166.5K | 10.4K | 1.20M | 48.37% | ↗ |
| 8 | 2023 | Krishna Vaddi, Ph.D. Chief Executive Officer | 572.7K | — | — | 1.74M | 330.6K | 2.6K | 2.64M | 65.71% | ↗ |
| 9 | 2023 | Jane Huang, M.D. President and Chief Medical Officer | 545.8K | — | — | 789.0K | 316.3K | 3.5K | 1.65M | 47.69% | ↗ |
| 10 | 2023 | Bryant D. Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | 359.3K | — | — | 1.09M | 159.1K | 9.5K | 1.61M | 67.31% | ↗ |
| 11 | 2022 | Krishna Vaddi, Ph.D. Chief Executive Officer | 558.3K | — | — | 2.50M | 238.4K | 9.2K | 3.30M | 75.61% | ↗ |
| 12 | 2022 | Jane Huang, M.D. President and Chief Medical Officer | 391.8K | 4.5K | 729.0K | 1.63M | 167.3K | — | 2.92M | 80.70% | ↗ |
| 13 | 2022 | Peggy A. Scherle Chief Scientific Officer | 416.7K | 300.0K | — | 761.9K | 142.8K | 9.2K | 1.63M | 46.73% | ↗ |
| 14 | 2021 | Krishna Vaddi, Ph.D. Chief Executive Officer | 544.2K | — | — | 6.22M | 265.7K | 8.7K | 7.04M | 88.38% | ↗ |
| 15 | 2021 | Brian Piper, M.B.A Former Chief Financial Officer | 389.5K | — | — | 2.52M | — | — | 2.91M | 86.61% | ↗ |
| 16 | 2021 | Peggy A. Scherle Chief Scientific Officer | 408.3K | — | — | 2.07M | 156.0K | 8.7K | 2.64M | 78.31% | ↗ |
| 17 | 2021 | Peggy Scherle, Ph.D. Chief Scientific Officer | 408.3K | — | — | 2.07M | 156.0K | — | 2.63M | 78.57% | ↗ |
| 18 | 2021 | Andrew Combs, Ph.D. EVP and Head of Chemistry | 406.5K | — | — | 2.07M | 156.0K | — | 2.63M | 78.62% | ↗ |
| 19 | 2020 | Krishna Vaddi, Ph.D. Chief Executive Officer | 417.1K | — | 1.41M | 9.58M | 228.7K | — | 11.63M | 94.45% | ↗ |
| 20 | 2020 | Christopher Pierce, M.B.A. Executive Vice President and Chief of Business Operations | 204.0K | — | — | 3.59M | 132.3K | — | 3.93M | 91.44% | ↗ |
| 21 | 2020 | Deborah Morosini, M.D. Executive Vice President and Chief of Clinical Affairs | 194.5K | — | — | 3.59M | 132.3K | — | 3.92M | 91.67% | ↗ |
| 22 | 2020 | Peggy Scherle, Ph.D. Chief Scientific Officer | 347.9K | — | — | 2.17M | 171.6K | — | 2.69M | 80.69% | ↗ |
| 23 | 2020 | Andrew Combs, Ph.D. EVP and Head of Chemistry | 321.5K | — | — | 1.53M | 161.0K | — | 2.02M | 76.07% | ↗ |
| 24 | 2020 | Brian Piper, M.B.A Former Chief Financial Officer | 328.9K | — | — | 1.47M | 161.0K | — | 1.96M | 75.02% | ↗ |
| 25 | 2019 | Krishna Vaddi, Ph.D. Chief Executive Officer | 315.0K | — | 815.0K | 828.1K | 121.3K | — | 2.08M | 79.02% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Krishna Vaddi | Founder, Chief Executive Officer & Director | 935.3K | — |
| Bryant David Lim | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | 681.1K | male |
| Peggy A. Scherle | Chief Scientific Officer | 674.2K | — |
| Andrew Combs | Executive Vice President & Chief Chemistry Officer | 562.5K | — |
| Naveen Babbar | Senior Vice President of Translation Medicine | — | male |
| Robert A. Doody Jr. | Senior Vice President of Investor Relations | — | male |
| Sean Brusky | Chief Business Officer | — | male |
| Sri Sahasranaman | Senior Vice President of Clinical Pharmacology | — | male |
| Aimee Crombie | Senior Vice President and Head of Strategic Planning & Operations | — | female |
| Wan-Jen Hong | Senior Vice President of Clinical Development | — | — |
| Charles Q. Morris MRCP | Chief Medical Officer | — | — |
| Madhu Pudipeddi | Senior Vice President of Technical Operations | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRLD
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
